What is Bone Biologics's market cap?

Bone Biologics (BBLG) has a market capitalization of $2.5M and trades on NASDAQ.

Who are Bone Biologics's competitors?

Bone Biologics's key competitors include Globus Medical, Medtronic, Stryker, and others. These companies compete in similar markets and product categories.

Who does Bone Biologics partner with?

Bone Biologics's notable partners include UCLA Technology Development Group, MTF Biologics, Therapeutic Goods Administration.

What subsidiaries does Bone Biologics have?

Bone Biologics's subsidiaries include Bone Biologics, Inc..

Where is Bone Biologics headquartered?

Bone Biologics is headquartered in United States of America and employs approximately 2 people. It has been publicly traded since 2015.

Bone Biologics

BBLG

Bone Biologics Corp is a clinical-stage medical device company focused on developing and commercializing bone regeneration solutions for spinal fusion and orthopedic applications.

Market cap

$2.48M-48.9%

Table of contents

Earnings

Q1 2026 report

May 14, 2026

EPS-$0.43In line

Read the full report

Next report

Aug 13, 2026 (in a month)

EPS estimate-$0.39

Competitors

By market cap

Johnson & Johnson$623.71B+66.9%

Stryker$125.40B-16.4%

Medtronic$105.46B-6.1%

Globus Medical$10.4B+37.3%

Orthofix Medical Inc.$464.0M+10.5%

Xtant Medical Holdings$58.9M-36.9%

Elutia$43.0M-49.8%

Bone Biologics$2.5M-49.9%

By revenue growth

Globus Medical+23.5%

Stryker+8.8%

Medtronic+8.4%

Johnson & Johnson+7.9%

Orthofix Medical Inc.+2.6%

Xtant Medical Holdings-0.3%

By net margin

Johnson & Johnson21.83%-2.6pp

Globus Medical18.92%+11.5pp

Stryker13.21%+0.9pp

Medtronic13.2%-0.7pp

Xtant Medical Holdings1.5%+11.3pp

Orthofix Medical Inc.-7.27%+10.5pp

Profile

Bone Biologics Corp is a clinical-stage medical device company focused on developing and commercializing bone regeneration solutions for spinal fusion and orthopedic applications. The company's core value proposition centers on its proprietary NELL-1 recombinant human protein platform, which provides target-specific control over bone growth to improve surgical outcomes in hard-to-heal patients.

Competitive position

A clinical-stage innovator leveraging an exclusive worldwide license for the NELL-1 protein platform to address unmet needs in bone regeneration.

GeographiesUnited States, Australia

Customer segmentsHealthcare Providers, Surgical Specialists

Business modelResearch and Development, Licensing, Product Development

SuppliersRecombinant protein manufacturers, Contract Research Organizations (CROs), Human tissue suppliers, Academic research institutions

CustomersOrthopedic surgeons, Neurosurgeons, Specialty surgical centers, Hospitals

CountryUnited States of America

Listed2015

Employees2.0

CEOJeffrey Frelick

SectorHealthcare

IndustryMedical - Devices

Websitebonebiologics.com

FilingsSEC EDGAR

Questions, answered.

What is Bone Biologics's market cap?: Bone Biologics (BBLG) has a market capitalization of $2.5M and trades on NASDAQ.
Who are Bone Biologics's competitors?: Bone Biologics's key competitors include Globus Medical, Medtronic, Stryker, and others. These companies compete in similar markets and product categories.
Who does Bone Biologics partner with?: Bone Biologics's notable partners include UCLA Technology Development Group, MTF Biologics, Therapeutic Goods Administration.
What subsidiaries does Bone Biologics have?: Bone Biologics's subsidiaries include Bone Biologics, Inc..
Where is Bone Biologics headquartered?: Bone Biologics is headquartered in United States of America and employs approximately 2 people. It has been publicly traded since 2015.